Profile data is unavailable for this security.
About the company
Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. It has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.
- Revenue in USD (TTM)2.80m
- Net income in USD-122.77m
- Incorporated2021
- Employees52.00
- LocationUpstream Bio Inc890 Winter Street, Suite 200WALTHAM 02451United StatesUSA
- Phone+1 (781) 208-2466
- Fax+1 (302) 655-5049
- Websitehttps://upstreambio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intellia Therapeutics Inc | 57.53m | -445.81m | 1.38bn | 403.00 | -- | 1.84 | -- | 23.98 | -4.27 | -4.27 | 0.5488 | 6.46 | 0.0548 | -- | 5.78 | 142,749.40 | -42.49 | -33.78 | -46.95 | -37.16 | -- | -- | -774.94 | -790.71 | -- | -- | 0.00 | -- | 59.55 | 6.07 | -7.86 | -- | -3.19 | -- |
| Azenta Inc | 594.95m | 28.69m | 1.38bn | 3.00k | 47.97 | 0.8048 | 16.17 | 2.32 | 0.6252 | -1.26 | 12.98 | 37.26 | 0.2891 | 4.03 | 4.00 | 198,317.70 | 1.39 | -0.3901 | 1.57 | -0.4328 | 44.59 | 45.32 | 4.82 | -1.73 | 2.61 | -- | 0.00 | -- | 3.55 | 8.85 | 200.38 | -- | -3.24 | -- |
| AnaptysBio Inc | 169.47m | -84.63m | 1.39bn | 136.00 | -- | -- | -- | 8.21 | -2.82 | -2.82 | 5.70 | -1.07 | 0.4004 | -- | 3.86 | 1,246,081.00 | -19.99 | -19.96 | -22.14 | -21.08 | -- | -- | -49.94 | -200.59 | -- | -- | 1.10 | -- | 432.03 | 62.73 | 11.24 | -- | -14.96 | -- |
| AtaiBeckley Inc | 3.02m | -154.19m | 1.40bn | 54.00 | -- | 5.79 | -- | 462.55 | -0.8136 | -0.8136 | 0.0161 | 0.6644 | 0.0138 | -- | 0.3354 | 55,981.48 | -70.56 | -45.69 | -77.07 | -50.03 | -- | -- | -5,104.20 | -2,658.81 | -- | -- | 0.00 | -- | -1.91 | -- | -271.09 | -- | 37.97 | -- |
| Novavax Inc | 1.06bn | 341.75m | 1.42bn | 952.00 | 4.86 | -- | 3.77 | 1.34 | 1.80 | 1.80 | 6.29 | -0.9643 | 0.7362 | 7.87 | 16.49 | 1,118,331.00 | 23.63 | -39.12 | 53.33 | -248.97 | 91.82 | -- | 32.10 | -67.41 | 2.24 | 17.15 | 2.66 | -- | -30.65 | 105.39 | 65.60 | -- | 47.71 | -- |
| Kodiak Sciences Inc | 0.00 | -217.34m | 1.42bn | 123.00 | -- | 52.17 | -- | -- | -4.12 | -4.12 | 0.00 | 0.447 | 0.00 | -- | -- | 0.00 | -73.58 | -33.79 | -82.91 | -35.95 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.36 | -- | -1.75 | -- |
| Monte Rosa Therapeutics Inc | 181.54m | 20.95m | 1.43bn | 147.00 | 78.11 | 4.92 | 48.74 | 7.86 | 0.2506 | 0.2506 | 2.20 | 3.98 | 0.4685 | -- | 65.30 | 1,354,761.00 | 5.41 | -33.14 | 6.24 | -39.19 | -- | -- | 11.54 | -563.84 | -- | -- | 0.00 | -- | -- | -- | 46.29 | -- | 23.56 | -- |
| Trevi Therapeutics Inc | 0.00 | -45.86m | 1.44bn | 26.00 | -- | 7.60 | -- | -- | -0.3713 | -0.3713 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -34.19 | -45.07 | -36.67 | -51.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -64.84 | -- | 31.21 | -- |
| Upstream Bio Inc | 2.80m | -122.77m | 1.50bn | 52.00 | -- | 3.97 | -- | 536.91 | -2.30 | -2.30 | 0.0527 | 7.01 | 0.009 | -- | 4.34 | 53,826.92 | -39.18 | -- | -40.67 | -- | -- | -- | -4,366.77 | -- | -- | -- | 0.00 | -- | -0.4202 | -- | -99.70 | -- | -- | -- |
| Relay Therapeutics Inc | 8.36m | -297.59m | 1.56bn | 188.00 | -- | 2.55 | -- | 186.47 | -1.75 | -1.75 | 0.0491 | 3.52 | 0.0104 | -- | -- | 32,015.33 | -37.20 | -31.62 | -39.14 | -32.85 | -- | -- | -3,561.43 | -1,130.74 | -- | -- | 0.00 | -- | -60.83 | -- | 1.25 | -- | -24.08 | -- |
| Agios Pharmaceuticals Inc | 44.79m | -401.27m | 1.58bn | 486.00 | -- | 1.23 | -- | 35.32 | -6.96 | -6.96 | 0.7768 | 22.04 | 0.0282 | 0.1959 | 11.00 | 92,162.55 | -25.26 | -10.38 | -26.90 | -11.09 | 87.22 | -- | -895.86 | -768.40 | 13.39 | -- | 0.00 | -- | 36.07 | -- | 291.35 | -- | -32.66 | -- |
| Oruka Therapeutics Inc | 0.00 | -101.63m | 1.59bn | 28.00 | -- | 3.29 | -- | -- | -2.36 | -2.36 | 0.00 | 10.06 | 0.00 | -- | -- | 0.00 | -22.01 | -32.95 | -22.98 | -34.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,468.16 | -- | 116.21 | -- |
| Biohaven Ltd | 0.00 | -780.11m | 1.62bn | 256.00 | -- | -- | -- | -- | -7.60 | -7.60 | 0.00 | -0.1622 | 0.00 | -- | -- | 0.00 | -169.65 | -- | -238.45 | -- | -- | -- | -- | -- | -- | -- | 1.07 | -- | -- | -- | -107.37 | -- | -- | -- |
| Alvotech SA | 573.35m | 69.50m | 1.62bn | 1.01k | 24.85 | -- | 15.42 | 2.83 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
| BioCryst Pharmaceuticals Inc | 599.82m | -8.78m | 1.62bn | 580.00 | -- | -- | -- | 2.71 | -0.0473 | -0.0473 | 2.78 | -1.84 | 1.28 | 2.10 | 7.32 | 1,034,166.00 | -1.87 | -40.01 | -2.96 | -53.68 | 97.39 | 97.34 | -1.46 | -75.69 | 1.83 | 0.9698 | 2.35 | -- | 36.00 | 55.97 | 60.77 | -- | 26.79 | -- |
Data as of Feb 10 2026. Currency figures normalised to Upstream Bio Inc's reporting currency: US Dollar USD
45.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 7.84m | 14.62% |
| Altshuler Shaham Provident Funds & Pension Ltd. (Invt Mgmt)as of 11 Oct 2024 | 3.39m | 6.33% |
| Norges Bank Investment Managementas of 30 Sep 2025 | 2.88m | 5.38% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.13m | 3.98% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.05m | 3.82% |
| UBS Securities LLCas of 31 Dec 2025 | 1.81m | 3.37% |
| Altshuler Shaham Mutual Funds Management Ltd.as of 30 Sep 2025 | 1.42m | 2.64% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 1.13m | 2.10% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 1.11m | 2.08% |
| Marshall Wace LLPas of 30 Sep 2025 | 868.00k | 1.62% |
More ▼
Data from 30 Jun 2025 - 26 Jan 2026Source: FactSet Research Systems Inc.
